Soumya Swaminathan Selected Research

Immune Reconstitution Inflammatory Syndrome

1/2022	Frequency of CXCR3+ CD8+ T-Lymphocyte Subsets in Peripheral Blood Is Associated With the Risk of Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome Development in Advanced HIV Disease.
6/2019	Multifocal tuberculosis-associated immune reconstitution inflammatory syndrome - a case report of a complicated scenario.
1/2019	Differential expression of CXCR3 and CCR6 on CD4+ T-lymphocytes with distinct memory phenotypes characterizes tuberculosis-associated immune reconstitution inflammatory syndrome.
1/2016	Role of LTA4H Polymorphism in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome Occurrence and Clinical Severity in Patients Infected with HIV.
1/2016	Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis.
2/2015	Plasma interleukin-18 levels are a biomarker of innate immune responses that predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome.
10/2014	Mycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome.
5/2014	Tuberculosis-immune reconstitution inflammatory syndrome in HIV: from pathogenesis to prediction.
1/2013	Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction.
6/2012	Immune reconstitution inflammatory syndrome in HIV-infected patients with and without prior tuberculosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Soumya Swaminathan Research Topics

Disease

71	Tuberculosis (Tuberculoses) 01/2022 - 01/2002
19	Infections 01/2019 - 12/2005
16	HIV Infections (HIV Infection) 10/2021 - 01/2004
15	Pulmonary Tuberculosis 01/2021 - 12/2005
14	Immune Reconstitution Inflammatory Syndrome 01/2022 - 10/2005
14	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 01/2021 - 10/2005
5	Coinfection 01/2020 - 01/2005
5	Disease Progression 01/2018 - 12/2005
4	Growth Disorders 10/2019 - 04/2011
3	COVID-19 12/2021 - 07/2021
3	Dyslipidemias (Dyslipidemia) 01/2021 - 02/2011
3	Malaria 12/2019 - 07/2008
3	Body Weight (Weight, Body) 10/2018 - 10/2009
3	Malnutrition (Nutritional Deficiencies) 01/2017 - 12/2015
3	Acquired Immunodeficiency Syndrome (AIDS) 09/2015 - 06/2004
2	Extensively Drug-Resistant Tuberculosis 06/2022 - 04/2016
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2018 - 01/2017
2	Cardiovascular Diseases (Cardiovascular Disease) 05/2017 - 02/2011
2	Inflammation (Inflammations) 01/2016 - 10/2015
2	Drug-Related Side Effects and Adverse Reactions 06/2011 - 04/2005
2	Opportunistic Infections (Opportunistic Infection) 07/2006 - 04/2005
1	Meningeal Tuberculosis (Tuberculous Meningitis) 10/2022
1	Cicatrix (Scar) 01/2018
1	Insulin Resistance 01/2018
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018
1	Latent Tuberculosis 01/2018
1	Atherosclerosis 05/2017
1	Nausea 04/2017
1	Prediabetic State (Prediabetes) 01/2017
1	Glucose Intolerance 01/2017
1	Alcoholism (Alcohol Abuse) 01/2017
1	Diabetes Mellitus 01/2017
1	Extrapulmonary Tuberculosis 04/2016
1	Lung Injury 04/2016

Drug/Important Bio-Agent (IBA)

35	Pharmaceutical PreparationsIBA 11/2021 - 04/2005
21	Rifampin (Rifampicin)FDA LinkGeneric 10/2022 - 01/2004
17	Isoniazid (Ftivazide)FDA LinkGeneric 01/2021 - 01/2004
12	Biomarkers (Surrogate Marker)IBA 10/2021 - 05/2012
9	Pyrazinamide FDA LinkGeneric 10/2018 - 01/2008
7	Moxifloxacin (Avelox)FDA Link 01/2020 - 11/2014
5	Linezolid (Zyvox)FDA Link 06/2022 - 11/2016
5	AntigensIBA 10/2014 - 01/2002
4	VaccinesIBA 07/2021 - 02/2009
4	LipidsIBA 01/2021 - 02/2011
4	Nevirapine (Viramune)FDA Link 09/2015 - 06/2011
4	Ethambutol (Myambutol)FDA LinkGeneric 11/2014 - 01/2008
3	bedaquiline (R207910)IBA 06/2022 - 12/2019
3	CytokinesIBA 01/2021 - 12/2005
3	AIDS VaccinesIBA 01/2019 - 02/2009
3	Tuberculin (PPD)IBA 01/2018 - 04/2005
3	Anti-Bacterial Agents (Antibiotics)IBA 11/2016 - 07/2013
3	efavirenz (Sustiva)FDA Link 12/2013 - 03/2009
3	Reverse Transcriptase InhibitorsIBA 12/2013 - 01/2010
2	OPC-67683IBA 06/2022 - 12/2019
2	Antiviral Agents (Antivirals)IBA 11/2021 - 10/2021
2	ChemokinesIBA 10/2021 - 12/2005
2	Broadly Neutralizing AntibodiesIBA 01/2019 - 01/2018
2	Triglycerides (Triacylglycerol)IBA 01/2018 - 05/2017
2	HDL CholesterolIBA 01/2018 - 05/2017
2	Papillomavirus Vaccines (HPV Vaccines)IBA 01/2018 - 01/2017
2	EpitopesIBA 10/2017 - 10/2012
2	fropenem (faropenem)IBA 11/2016 - 11/2016
2	Nucleic AcidsIBA 01/2016 - 11/2012
2	EnzymesIBA 01/2016 - 04/2011
2	NucleosidesIBA 12/2013 - 01/2010
2	NeopterinIBA 05/2009 - 04/2005
1	Levofloxacin (Levaquin)FDA Link 10/2022
1	Clofazimine (Lamprene)FDA Link 06/2022
1	mRNA VaccinesIBA 12/2021
1	Interferon beta-1a FDA Link 11/2021
1	Lopinavir FDA Link 11/2021
1	InterferonsIBA 11/2021
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 11/2021
1	remdesivirIBA 11/2021
1	Immunologic Factors (Immunomodulators)IBA 10/2021
1	Interleukin-2 (IL2)IBA 01/2021
1	Interleukin-17 (Interleukin 17)IBA 01/2021
1	Pyridoxine (Pyridoxin)FDA LinkGeneric 12/2020
1	resazurinIBA 12/2019
1	Proteins (Proteins, Gene)FDA Link 10/2019
1	Metformin (Glucophage)FDA LinkGeneric 01/2019
1	CholesterolIBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	C-Reactive ProteinIBA 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	GoldIBA 01/2018
1	LDL CholesterolIBA 01/2018
1	Interleukin-10 (Interleukin 10)IBA 01/2018
1	Neutralizing AntibodiesIBA 01/2018
1	AcetyltransferasesIBA 01/2017
1	Antitubercular AgentsIBA 01/2017
1	tat Gene Products (tat Protein)IBA 01/2017
1	Glucose (Dextrose)FDA LinkGeneric 01/2017
1	Leukotriene A4IBA 01/2016

Therapy/Procedure

31	Therapeutics 01/2021 - 04/2005
10	Art Therapy 01/2022 - 02/2011
5	Duration of Therapy 01/2020 - 11/2002
4	Highly Active Antiretroviral Therapy (HAART) 12/2014 - 07/2006
4	Drug Therapy (Chemotherapy) 01/2012 - 11/2007
1	Length of Stay 11/2021